StemSynergy Therapeutics, Inc. (SSTI) is a biopharmaceutical company focused on the discovery of small-molecule drugs that target developmental pathways fundamental to cancer and tissue regeneration. The goal of our cancer program is to develop novel therapeutics to treat cancer by targeting cellular processes that are deregulated in cancer stem cells. Our drugs act in combination with standard-of-care agents that target the bulk of the cancer cells, with the overall aim of eliminating the cancer. SSTI is focused on breakthrough technologies in WNT and Sonic Hedgehog (SHH) signaling. With a multi-pronged scientific approach and a number of agents targeting cancer stem cell pathways, SSTI is well positioned to address critical unmet medical needs.